MYNZ Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Mainz Biomed NV (MYNZ) is not a strong buy for a beginner, long-term investor at this time. The stock is in a bearish technical trend with oversold conditions, and there are no significant positive catalysts or trading signals to support immediate investment. The company's financials show no growth in revenue or profitability, and the recent financing agreement indicates a need for liquidity rather than strong operational performance. Given the investor's profile and the lack of strong signals, holding off on this stock is recommended.
The stock is in a bearish trend with the MACD histogram below zero (-0.044) and negatively contracting. The RSI is at 17.687, indicating oversold conditions. The moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key support is at 0.614, with resistance at 1.041. Pre-market price is down 3.05% to 0.6106.
The company has secured a $6 million financing agreement to enhance liquidity and focus on pancreatic cancer detection in the U.S., which could be a long-term growth area.
The company completed a private placement to fund operations and address liabilities, indicating financial strain. Pre-market price is down 3.05%, and technical indicators suggest a bearish trend.
In Q4 2023, revenue remained flat at $214,761 YoY. Net income was -$5,183,327, showing no improvement YoY. EPS was -0.27, and gross margin was 62.74%, with no YoY growth.
No recent analyst rating or price target changes are available.
